Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
- PMID: 11457879
- PMCID: PMC203021
- DOI: 10.1172/JCI11771
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Abstract
Vascular complications arising from multiple environmental and genetic factors are responsible for many of the disabilities and short life expectancy associated with diabetes mellitus. Here we provide the first direct in vivo evidence that interactions between advanced glycation end products (AGEs; nonenzymatically glycosylated protein derivatives formed during prolonged hyperglycemic exposure) and their receptor, RAGE, lead to diabetic vascular derangement. We created transgenic mice that overexpress human RAGE in vascular cells and crossbred them with another transgenic line that develops insulin-dependent diabetes shortly after birth. The resultant double transgenic mice exhibited increased hemoglobin A(1c) and serum AGE levels, as did the diabetic controls. The double transgenic mice demonstrated enlargement of the kidney, glomerular hypertrophy, increased albuminuria, mesangial expansion, advanced glomerulosclerosis, and increased serum creatinine compared with diabetic littermates lacking the RAGE transgene. To our knowledge, the development of this double transgenic mouse provides the first animal model that exhibits the renal changes seen in humans. Furthermore, the phenotypes of advanced diabetic nephropathy were prevented by administering an AGE inhibitor, (+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195), thus establishing the AGE-RAGE system as a promising target for overcoming this aspect of diabetic pathogenesis.
Figures







Similar articles
-
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.Diabetes. 2006 Sep;55(9):2510-22. doi: 10.2337/db06-0221. Diabetes. 2006. PMID: 16936199
-
Receptor for advanced glycation end products is a promising target of diabetic nephropathy.Ann N Y Acad Sci. 2005 Jun;1043:562-6. doi: 10.1196/annals.1333.064. Ann N Y Acad Sci. 2005. PMID: 16037279
-
An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S68-71. doi: 10.1053/ajkd.2003.50088. Am J Kidney Dis. 2003. PMID: 12612956
-
Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.Ann N Y Acad Sci. 2005 Jun;1043:605-8. doi: 10.1196/annals.1338.068. Ann N Y Acad Sci. 2005. PMID: 16037283 Review.
-
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?Ann N Y Acad Sci. 2005 Jun;1043:750-8. doi: 10.1196/annals.1333.087. Ann N Y Acad Sci. 2005. PMID: 16037302 Review.
Cited by
-
Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines.Int J Mol Sci. 2013 Apr 11;14(4):7959-78. doi: 10.3390/ijms14047959. Int J Mol Sci. 2013. PMID: 23579957 Free PMC article.
-
Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.Handb Exp Pharmacol. 2021;264:395-423. doi: 10.1007/164_2020_391. Handb Exp Pharmacol. 2021. PMID: 32809100
-
Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.Clin J Am Soc Nephrol. 2010 Dec;5(12):2213-9. doi: 10.2215/CJN.03360410. Epub 2010 Sep 16. Clin J Am Soc Nephrol. 2010. PMID: 20847094 Free PMC article.
-
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.Am J Pathol. 2004 Apr;164(4):1389-97. doi: 10.1016/S0002-9440(10)63225-7. Am J Pathol. 2004. PMID: 15039226 Free PMC article.
-
Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?Clin Biochem Rev. 2005 Nov;26(4):123-34. Clin Biochem Rev. 2005. PMID: 16648883 Free PMC article.
References
-
- Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994;330:15–18. - PubMed
-
- Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int. 1996;50:2041–2046. - PubMed
-
- Velasquez MT, Kimmel PL, Michaelis OE., IV Animal models of spontaneous diabetic kidney disease. FASEB J. 1990;4:2850–2859. - PubMed
-
- Doi T, et al. Glomerular lesions in nonobese diabetic mouse: before and after the onset of hyperglycemia. Lab Invest. 1990;63:204–212. - PubMed
-
- Williamson JR, et al. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin-induced diabetes. Prevention by aldose reductase inhibitors and castration. Diabetes. 1987;36:813–821. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases